Table 2.
Total N = 136 |
Candidemia due to C. albicans N = 78 |
Candidemia due to non-albicans Candida species N = 58 |
P value | |
---|---|---|---|---|
Recent surgery (<3 months) | 75 (55.1) | 43 (55.1) | 32 (55.2) | 0.99 |
Intra-abdominal | 56 (41.2) | 32 (41.0) | 24 (41.6) | 0.95 |
Vascular | 9 (6.6) | 6 (7.7) | 3 (5.2) | 0.54 |
Time from surgery to candidemia (days) | 23.6 ± 20.7 | 22.6 ± 19.3 | 25.0 ± 22.7 | 0.62 |
Invasive mechanical ventilation | 106 (77.9) | 62 (79.5) | 44 (75.9) | 0.61 |
CVC | 122 (89.8) | 68 (87.2) | 54 (93.2) | 0.26 |
Time from CVC placement to candidemia (days) | 15.2 ± 16.9 | 13.1 ± 14.9 | 17.8 ± 18.9 | 0.13 |
UC | 122 (89.8) | 68 (87.2) | 54 (63.2) | 0.26 |
Time from UC placement to candidemia (days) | 16.4 ± 17.0 | 14.7 ± 16.7 | 18.6 ± 17.4 | 0.22 |
Prior antibiotherapy | 84 (61.8) | 48 (61.5) | 36 (62.1) | 0.95 |
Duration of antibiotherapy before candidemia (days) | 18.2 ± 13.5 | 17.8 ± 14.4 | 18.7 ± 12.4 | 0.77 |
Previous exposure to azole agents | 23 (16.9) | 11 (14.1) | 12 (20.7) | 0.31 |
Vasoactive drug use | 31 (22.8) | 20 (25.6) | 11 (19.0) | 0.36 |
Results are expressed as mean ± SD values or numbers (%) of patients. CVC: central venous catheter; UC: urinary catheter